Drugs / Eprolidone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05924958 | Sep 2023 → Aug 2026 overdue | heart failure | Cheng LuFeng,Principal Investigator | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eprolidone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05924958 ↗ |